trending Market Intelligence /marketintelligence/en/news-insights/trending/zn1yjhpmabgzbplbrti3uw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Santhera completes CHF23.5M accelerated bookbuild offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Santhera completes CHF23.5M accelerated bookbuild offering

Santhera Pharmaceuticals Holding AG completed a share placement offering to raise about CHF23.5 million in gross proceeds to fund a pending drug licensing deal with Idorsia Ltd.

The Swiss specialty pharmaceutical company placed a total of 3,133,334 shares in the offering at CHF7.50 apiece. Santhera's share capital will increase from about CHF7.5 million to CHF10.7 million as a result of the transaction.

Santhera plans to use $20 million of the net proceeds to pay the cash component of a pending deal with Idorsia to license the steroid vamorolone. The payment will complete that transaction. Vamorolone is a steroid seen as a safer alternative for patients with Duchenne muscular dystrophy.

The company expects the shares to start trading on the SIX Swiss Exchange around Dec. 18.